Pharmaceutical Market Europe • February 2021 • 3

COMMENT

Vaccines lead the way!

The question of why some people are resistant to having a vaccine for COVID-19 is a crucial one, as the world strives to get back to some sense of normality. As the British newspapers have been heralding in recent weeks, the vaccine is our way back, but the aim of vaccines is to work towards a high level of immunity in the population, and this will only be possible if enough people receive the vaccine. As COVID-19 continues to prove just how dangerous it is to some parts of the population, Mike Dixon gives some advice in his column on page 14 on how the healthcare community can contribute to this crucial conversation.

In Mike Fraser’s article on page 16, he looks at what’s in store for rare genetic diseases in 2021. Mike, General Manager, EMEA at Novartis Gene Therapies, talks about how the numerous breakthroughs in recent years have made it clear that personalised medicine based on our own genomes is the future of healthcare.

On page 20, Richard O’Kennedy, VP for Research, Development and Innovation at Qatar Foundation and the VP for Research at Hamad Bin Khalifa University looks at precision medicine and why, with the value of precision medicine still too often implicit, we need clinicians and the scientific community to produce hard evidence that it is cost-effective.

Danny Buckland talks to Angela Young, chief people officer at Lucid Group and Claire Long, Deputy Managing Director, Communications at 90TEN about the remote working revolution on page 26. The article looks at how the pandemic has recalibrated the rhythms of the working day – raising productivity, reducing absenteeism and decreasing employee attrition – but asks if this is at the expense of corporate culture.

I hope you enjoy this issue!

Image

Iona Everson
Group Managing Editor

Keep up to date with the latest developments in the UK and global healthcare marketplace – sign up to daily or weekly news alerts and fortnightly or monthly bulletins on specific topics at  www.pmlive.com/register

Image

THE TEAM
Editorial:
Group Managing Editor
Iona Everson
Reporter
Lucy Parsons

Studio:
Executive Director
Karl Equi
Middleweight Graphic Designer
Helen Penfold

Sales:
Business Director
Tara Lovegrove

EDITORIAL ADVISORY BOARD
Philip Atkinson
Founder of Hive-Logic, Lifescience Transformation
Uday Bose
Corporate vice president, head of global marketing oncology, Boehringer Ingelheim
Dr Luc Hermans
VP commercial planning and operations Europe, Asia, Middle East, Gilead Sciences
Stefan Janssens
President EMEA, Cegedim Dendrite
John Morris
Partner, KPMG
Paul Pay
Chief business development officer, Norgine
Mark Rothera
Chief executive officer, Orchard Therapeutics
Ian Talmage
Senior vice president, global marketing, general medicine, Bayer Pharmaceuticals

PUBLISHED BY
PMGroup
Mansard House, Church Road, Little Bookham, Surrey, KT23 3JG, UK
Tel: +44 (0)1372 414200
Fax: +44 (0)1372 414201

CONTACT US
General enquiries: info@pmlive.com
Editorial: editor@pmlive.com
Advertising: sales@pmlive.com
Subscriptions: subscriptions@pmlive.com

Views expressed by the contributors do not necessarily represent those of the publisher, editor or staff.
© 2021 PMGroup
All rights reserved. No part of this publication may be copied, reproduced, transmitted, photocopied, recorded or stored on any retrieval system without the prior written consent of the publishers.
The magazine is also available at the following subscription rates: £120 UK, £180 Europe, £210 RoW

Image